Using hepatitis C prevalence to estimate HIV epidemic potential among people who inject drugs in the Middle East and North Africa

Ghina R. Mumtaz, Helen A. Weiss, Peter Vickerman, Natasha Larke, Laith Aburaddad

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Objectives: The objective of this study is to understand the association between HIV and hepatitis C virus (HCV) among people who inject drugs (PWIDs) in the Middle East and North Africa (MENA), and to estimate HIV epidemic potential among PWIDs using HCV prevalence. Design/methods: Using data from a systematic review of HIV and HCV among PWID in MENA, we conducted two analyses, stratified by HIV epidemic state: a meta-analysis of the risk ratio of HCV to HIV prevalence (RRHCV/HIV) using DerSimonian-Laird random-effects models, and multivariable linear regression predicting log HIV prevalence. The HCV-HIV association from both analyses was used to estimate HIV prevalence at endemic equilibrium. We compared predicted with current HIV prevalence to classify HIV epidemic potential at country-level as low, medium or high, using predefined criteria. Results: The review identified 88 HCV prevalence measures among PWID in MENA, of which 54 had a paired HIV prevalence measure. The pooled RRHCV/HIV were 16, 4 and 3 in low-level, emerging and established HIV epidemics, respectively. There was a significant linear relationship between HCV and HIV at endemic equilibrium (P=0.002). The predicted endemic HIV prevalence ranged between 8% (Tunisia) and 22% (Pakistan). Of the nine countries with data, five have high and three medium HIV epidemic potential. Only one country, Pakistan, appears to have reached saturation. Conclusion: HCV prevalence could be a predictor of future endemic HIV prevalence. In MENA, we predict that there will be further HIV epidemic growth among PWID. The proposed methodology can identify PWID populations that should be prioritized for HIV prevention interventions.

Original languageEnglish
Pages (from-to)1701-1710
Number of pages10
JournalAIDS
Volume29
Issue number13
DOIs
Publication statusPublished - 24 Aug 2015
Externally publishedYes

Fingerprint

Northern Africa
Eastern Africa
Middle East
Hepatitis C
HIV
Pharmaceutical Preparations
Hepacivirus
Pakistan
Odds Ratio
Tunisia

Keywords

  • Epidemic
  • Hepatitis C virus
  • HIV
  • Middle East and North Africa
  • People who inject drugs
  • Prediction

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Infectious Diseases

Cite this

Using hepatitis C prevalence to estimate HIV epidemic potential among people who inject drugs in the Middle East and North Africa. / Mumtaz, Ghina R.; Weiss, Helen A.; Vickerman, Peter; Larke, Natasha; Aburaddad, Laith.

In: AIDS, Vol. 29, No. 13, 24.08.2015, p. 1701-1710.

Research output: Contribution to journalArticle

Mumtaz, Ghina R. ; Weiss, Helen A. ; Vickerman, Peter ; Larke, Natasha ; Aburaddad, Laith. / Using hepatitis C prevalence to estimate HIV epidemic potential among people who inject drugs in the Middle East and North Africa. In: AIDS. 2015 ; Vol. 29, No. 13. pp. 1701-1710.
@article{d09768cf21674963b2c8d0398b1b2e00,
title = "Using hepatitis C prevalence to estimate HIV epidemic potential among people who inject drugs in the Middle East and North Africa",
abstract = "Objectives: The objective of this study is to understand the association between HIV and hepatitis C virus (HCV) among people who inject drugs (PWIDs) in the Middle East and North Africa (MENA), and to estimate HIV epidemic potential among PWIDs using HCV prevalence. Design/methods: Using data from a systematic review of HIV and HCV among PWID in MENA, we conducted two analyses, stratified by HIV epidemic state: a meta-analysis of the risk ratio of HCV to HIV prevalence (RRHCV/HIV) using DerSimonian-Laird random-effects models, and multivariable linear regression predicting log HIV prevalence. The HCV-HIV association from both analyses was used to estimate HIV prevalence at endemic equilibrium. We compared predicted with current HIV prevalence to classify HIV epidemic potential at country-level as low, medium or high, using predefined criteria. Results: The review identified 88 HCV prevalence measures among PWID in MENA, of which 54 had a paired HIV prevalence measure. The pooled RRHCV/HIV were 16, 4 and 3 in low-level, emerging and established HIV epidemics, respectively. There was a significant linear relationship between HCV and HIV at endemic equilibrium (P=0.002). The predicted endemic HIV prevalence ranged between 8{\%} (Tunisia) and 22{\%} (Pakistan). Of the nine countries with data, five have high and three medium HIV epidemic potential. Only one country, Pakistan, appears to have reached saturation. Conclusion: HCV prevalence could be a predictor of future endemic HIV prevalence. In MENA, we predict that there will be further HIV epidemic growth among PWID. The proposed methodology can identify PWID populations that should be prioritized for HIV prevention interventions.",
keywords = "Epidemic, Hepatitis C virus, HIV, Middle East and North Africa, People who inject drugs, Prediction",
author = "Mumtaz, {Ghina R.} and Weiss, {Helen A.} and Peter Vickerman and Natasha Larke and Laith Aburaddad",
year = "2015",
month = "8",
day = "24",
doi = "10.1097/QAD.0000000000000761",
language = "English",
volume = "29",
pages = "1701--1710",
journal = "AIDS",
issn = "0269-9370",
publisher = "Lippincott Williams and Wilkins",
number = "13",

}

TY - JOUR

T1 - Using hepatitis C prevalence to estimate HIV epidemic potential among people who inject drugs in the Middle East and North Africa

AU - Mumtaz, Ghina R.

AU - Weiss, Helen A.

AU - Vickerman, Peter

AU - Larke, Natasha

AU - Aburaddad, Laith

PY - 2015/8/24

Y1 - 2015/8/24

N2 - Objectives: The objective of this study is to understand the association between HIV and hepatitis C virus (HCV) among people who inject drugs (PWIDs) in the Middle East and North Africa (MENA), and to estimate HIV epidemic potential among PWIDs using HCV prevalence. Design/methods: Using data from a systematic review of HIV and HCV among PWID in MENA, we conducted two analyses, stratified by HIV epidemic state: a meta-analysis of the risk ratio of HCV to HIV prevalence (RRHCV/HIV) using DerSimonian-Laird random-effects models, and multivariable linear regression predicting log HIV prevalence. The HCV-HIV association from both analyses was used to estimate HIV prevalence at endemic equilibrium. We compared predicted with current HIV prevalence to classify HIV epidemic potential at country-level as low, medium or high, using predefined criteria. Results: The review identified 88 HCV prevalence measures among PWID in MENA, of which 54 had a paired HIV prevalence measure. The pooled RRHCV/HIV were 16, 4 and 3 in low-level, emerging and established HIV epidemics, respectively. There was a significant linear relationship between HCV and HIV at endemic equilibrium (P=0.002). The predicted endemic HIV prevalence ranged between 8% (Tunisia) and 22% (Pakistan). Of the nine countries with data, five have high and three medium HIV epidemic potential. Only one country, Pakistan, appears to have reached saturation. Conclusion: HCV prevalence could be a predictor of future endemic HIV prevalence. In MENA, we predict that there will be further HIV epidemic growth among PWID. The proposed methodology can identify PWID populations that should be prioritized for HIV prevention interventions.

AB - Objectives: The objective of this study is to understand the association between HIV and hepatitis C virus (HCV) among people who inject drugs (PWIDs) in the Middle East and North Africa (MENA), and to estimate HIV epidemic potential among PWIDs using HCV prevalence. Design/methods: Using data from a systematic review of HIV and HCV among PWID in MENA, we conducted two analyses, stratified by HIV epidemic state: a meta-analysis of the risk ratio of HCV to HIV prevalence (RRHCV/HIV) using DerSimonian-Laird random-effects models, and multivariable linear regression predicting log HIV prevalence. The HCV-HIV association from both analyses was used to estimate HIV prevalence at endemic equilibrium. We compared predicted with current HIV prevalence to classify HIV epidemic potential at country-level as low, medium or high, using predefined criteria. Results: The review identified 88 HCV prevalence measures among PWID in MENA, of which 54 had a paired HIV prevalence measure. The pooled RRHCV/HIV were 16, 4 and 3 in low-level, emerging and established HIV epidemics, respectively. There was a significant linear relationship between HCV and HIV at endemic equilibrium (P=0.002). The predicted endemic HIV prevalence ranged between 8% (Tunisia) and 22% (Pakistan). Of the nine countries with data, five have high and three medium HIV epidemic potential. Only one country, Pakistan, appears to have reached saturation. Conclusion: HCV prevalence could be a predictor of future endemic HIV prevalence. In MENA, we predict that there will be further HIV epidemic growth among PWID. The proposed methodology can identify PWID populations that should be prioritized for HIV prevention interventions.

KW - Epidemic

KW - Hepatitis C virus

KW - HIV

KW - Middle East and North Africa

KW - People who inject drugs

KW - Prediction

UR - http://www.scopus.com/inward/record.url?scp=84938278503&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84938278503&partnerID=8YFLogxK

U2 - 10.1097/QAD.0000000000000761

DO - 10.1097/QAD.0000000000000761

M3 - Article

C2 - 26372281

AN - SCOPUS:84938278503

VL - 29

SP - 1701

EP - 1710

JO - AIDS

JF - AIDS

SN - 0269-9370

IS - 13

ER -